New Delhi: Institute of Cellular Therapies (ICT), a Noida-based institute has now accepted an offer from Malaysia to provide targeted dendritic cell therapy to patients there. The therapy is being adopted by Malaysia after the successful treatment of hundreds of cancer patients in India.
As per sources, ICT has devised a latest treatment procedure that uses cell-based cancer immuno-therapy-treatment, using the patient's own mononuclear cells transformed into cancer-specific dendritic (immune system regulatory) cells. In this therapy, medical experts extract the mononuclear (CD14+) cells from the patient's own blood, transform these cells into cancer-fighting cells and implant them back in the patient's body.
Jamal A Khan, Senior Doctor & ICT Director, has said that Dendritic cell therapy is a targeted add-on treatment for cancer patients. It helps the recovery process and reduces the chance of relapse of the disease among patients. He mentioned that they are happy that the Malaysian government authorities now want this treatment to be made available there. Mr Khan also added that ICT will set up a cell culture lab for clinical trials in Malaysia, very soon.
Further, ICT will work in tandem with Malaysia's health ministry to set up the lab and to make this treatment popular. Malaysia is currently importing the medicine from ICT and after the lab comes up in the country, ICT will manufacture the medicine - Denvax - in Malaysia. Moreover, the best part of the therapy is that it targets the cancer cells, without affecting other cells around the cancerous part of the body.
